Printer Friendly

Bristol's BARACLUDE Tablet for Chronic Hepatitis B Virus Infection Granted Priority Review by Government.

Tokyo, Japan, Nov 11, 2005 - (JCNN) - Bristol Pharmaceutical K.K. announced on November 10 that the Ministry of Health, Labor and Welfare has granted the company with a priority review status for BARACLUDE Tablet, an agent for treating chronic hepatitis B virus (HBV) infection, as of November 8.

Discovered by Bristol-Myers Squibb, BARACLUDE (entecavil) is an oral nucleoside analogue that selectivity inhibits HBV polymerase. In Japan, it is estimated that more than 10 million people develop chronic HBV infection and about 35,000 people die from liver cancer triggered by HBV infection every year.

Bristol Pharmaceutical has filed applications for BARACLUDE, which was initially approved in the US in March 2005, on August 31.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:1USA
Date:Nov 14, 2005
Words:130
Previous Article:Yokohama Rubber Announces Auto Parts Manufacturing and Conveyor Belt Joint Ventures in China.
Next Article:Toyota Registers First Hybrid Vehicles in China.
Topics:


Related Articles
GILEAD SUBMITS MAA TO EMEA FOR ADEFOVIR DIPIVOXIL 10 MG.
VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.
FDA AIDS announcements, first quarter 2005.
Combination Therapy Using Chugai Pharmaceutical's Chronic Hepatitis-C Agents PEGASYS and Rivabirin Granted Priority Review Status by Government.
MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.
Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic Hepatitis B Patients.
TELBIVUDINE APPROVED IN SWITZERLAND FOR CHRONIC HEPATITIS B.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |